Maintenance treatment for recurrent ovarian cancer
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial tests a new drug called torvutatug samrotecan, alone or with bevacizumab, as a maintenance therapy after chemotherapy for ovarian cancer that has come back. It aims to help keep the cancer from growing for a longer time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have high-grade serous or endometrioid ovarian, fallopian tube, or primary peritoneal cancer.
- You have had at least one, but no more than two, prior lines of chemotherapy for your cancer.
- Your cancer came back at least 6 months after your last platinum chemotherapy.
- You have completed at least 6 cycles of platinum-based chemotherapy in your current treatment and your disease has not progressed.
- If you are assigned to bevacizumab, you must have received it with your last 3 cycles of chemotherapy.
- If you have a BRCA mutation, you must have already tried a PARP inhibitor (unless you couldn't take it).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug combination (torvutatug samrotecan plus bevacizumab) as maintenance therapy to help keep advanced ovarian cancer from growing after initial chemotherapy. It is for people whose tumors do not have a specific genetic change called HRD.
This study tests a new maintenance therapy for people with advanced ovarian cancer that has responded well to initial chemotherapy. The goal is to see if it helps keep the cancer from coming back.
This study tests a new maintenance treatment (sacituzumab tirumotecan) versus standard care for people with ovarian cancer that has come back after responding to platinum-based chemotherapy. The goal is to see if it can keep the cancer from growing longer and improve quality of life.
This trial studies whether adding pembrolizumab to bevacizumab (and sometimes an anti-CD40 drug) can help control recurrent ovarian, fallopian tube, or primary peritoneal cancer. It also looks at whether the treatment can shrink tumors and keep them from growing for longer.
This study tests whether adding a new pill (INCB123667) to the usual maintenance drug bevacizumab (Avastin) can keep ovarian cancer from coming back, compared to bevacizumab alone. It is for women who have finished their first chemo and are in remission or have stable disease.
This trial tests a new experimental drug (JPI-547) combined with bevacizumab (a targeted therapy) as maintenance treatment for recurrent ovarian cancer after initial response to platinum-based chemo. The goal is to see if this combination can keep the cancer from growing longer than standard care.
Hear when a new Platinum-sensitive Relapsed Epithelial Ovarian Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.